Predictive Oncology reported financial results for Q3 2025, highlighting a digital asset treasury strategy focused on ATH tokens, with $50.8 million in cash proceeds and $292.7 million in tokens. The company holds 5.7 billion ATH tokens worth $152.8 million. Predictive Oncology aims to democratize AI access through Aethir’s ecosystem. The company appointed Shawn Matthews to its Board of Directors and collaborates with Every Cure for drug repurposing. Financially, the company had $181,667 in cash and a stockholders’ deficit of $77.4 million. Revenue for Q3 2025 was $3,618, and operating expenses increased to $3.27 million. Net loss was $(77.7) million for continuing operations.

The company will host a conference call on November 17th to discuss these results in more detail. Predictive Oncology is a leader in AI-driven drug discovery, with a validated platform predicting tumor response to drugs. The company also operates a digital asset treasury focused on ATH tokens, creating the Strategic Compute Reserve. Forward-looking statements in the press release outline the company’s goals and potential risks. The company’s financial statements show a stockholders’ deficit of $77.4 million and a net loss of $(77.7) million for Q3 2025.

Read more at GlobeNewswire: Predictive Oncology Reports Third Quarter 2025 Financial